Monitor cash runway closely — at current burn rate, the $3.8M cash balance provides limited runway without additional financing or collection of the Juventas award. The CID-103 Phase 1/2 data readouts in AMR and ITP are the primary catalysts, but the going-concern risk and OTCQB listing limit upside. The $15M convertible note from the Chairman adds dilution risk and signals insider support but also potential conflict of interest.
Price Chart
Executive Summary
CASI Pharmaceuticals reported H1 2026 results with revenue declining 5.8% to $9.8M, net loss narrowing to $20.0M from $24.1M, and cash dropping to $3.8M. The company remains in a precarious financial position with negative shareholders' equity of $58.3M, Nasdaq delisting completed, and a going-concern warning. Positive developments include a favorable Juventas arbitration award exceeding RMB 100M and clinical progress for CID-103, but these do not offset the fundamental deterioration.
Key Facts
- H1 2026 revenue declined 5.8% YoY to $9.8M from $10.4M
- Net loss improved to $20.0M from $24.1M in H1 2025
- Cash and cash equivalents fell to $3.8M from $5.6M at Dec 31, 2025
- Shareholders' deficit widened to $58.3M from $37.3M
- Total current liabilities of $66.6M far exceed total current assets of $10.0M
- Convertible notes due to related party increased to $19.2M from $4.2M
- Nasdaq delisting completed; shares now trade on OTCQB under CASIF
- Favorable Juventas arbitration award of well over RMB 100 million received post-quarter
- $15M convertible note financing completed with ETP Global III Fund LP (controlled by Chairman)
- First patient dosed in Phase 1/2 CID-103 trial for AMR in China; ITP dose-escalation Part A enrollment completed
Financial Impact
Revenue decline of $0.6M (5.8%) YoY; net loss improvement of $4.1M; cash burn of $1.9M in H1 2026; Juventas award >RMB 100M (~$14M) but collection uncertain
Risk Factors
- Going-concern risk with negative equity and low cash
- Nasdaq delisting reduces liquidity and institutional interest
- Revenue decline from EVOMELA-to-MAFALAN transition may persist
- Convertible note and potential future dilution
- Uncertainty around collection of Juventas arbitration award
- Going-private proposal by Chairman creates overhang and conflict of interest
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (CASIF) — Batch item 1 | 0001104659-26-096404 |
| Document: tm2622837d2_6k.htm | 0001104659-26-096404 |
| Document: 0001104659-26-096404-index-headers.html | 0001104659-26-096404 |
| Document: 0001104659-26-096404-index.html | 0001104659-26-096404 |
| Document: 0001104659-26-096404.txt | 0001104659-26-096404 |
| 6-K Filing (CASIF) — Batch item 6 | 0001104659-26-096404 |
| Document: tm2622837d2_6k.htm | 0001104659-26-096404 |
| Document: 0001104659-26-096404-index-headers.html | 0001104659-26-096404 |
| Document: 0001104659-26-096404-index.html | 0001104659-26-096404 |
| Document: 0001104659-26-096404.txt | 0001104659-26-096404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 6-K | $0.1400 | awaiting T+60 | — | $0.1000 (−28.57%) |
Aug 14, 2026 10w ago | 6-K | $0.1500 | awaiting T+60 | — | $0.1000 (+33.33%) |
Jul 15, 2026 14w ago | 6-K | $0.1400 $0.1100 | ▼ −21.43% | ▼ −24.22% | $0.1000 (−28.57%) |
Jun 29, 2026 17w ago | 6-K | $0.1200 $0.1300 | ▲ +8.33% | ▲ +5.29% | $0.1000 (−16.67%) |
Jun 2, 2026 21w ago | 6-K | $0.1100 $0.1300 | ▲ +18.18% | ▲ +17.06% | $0.1000 (−9.09%) |
Apr 23, 2026 26w ago | 3 | $0.1300 $0.1700 | ▲ +30.77% | ▲ +25.75% | $0.1000 (−23.08%) |
Apr 20, 2026 27w ago | 6-K | $0.1700 $0.1344 | ▼ −20.94% | ▼ −27.84% | $0.1000 (−41.18%) |
Apr 20, 2026 27w ago | 6-K | $0.1700 $0.1250 | ▲ +26.47% | ▲ +33.25% | $0.1000 (+41.18%) |
Apr 15, 2026 27w ago | 6-K | $0.1500 $0.1451 | ▼ −3.27% | ▼ −11.40% | $0.1000 (−33.33%) |
Apr 3, 2026 29w ago | 3 | $0.1400 $0.2400 | ▲ +71.43% | ▲ +57.96% | $0.1000 (−28.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers